Simcere climbs on license deal with Vigonvita
I'm PortAI, I can summarize articles.
** Simcere Pharmaceutical Group climbs 3.7% to HK$13.59; set for biggest one-day pct gain since November 13** Stock set to snap two straight sessions of fall** Generic drug producer obtains exclusive license rights to Vigonvita Life Science's Deuterated Remdesivir Hydrobromide in the Greater China region** Drug used to treat respiratory syncytial virus, human metapneumovirus (HMPV) infection** Co says collaboration will strengthen group's product deployment in anti-infection area** Vigonvita's stock slips 2.5% to HK$74.1** YTD, Simcere shares up 90%; Vigonvita's stock surges 236.8% since listing in Hong Kong on November 6
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments